What's in Shanghai Biomabs Pharmaceutical Co., Ltd.'s pipeline?

Shanghai Biomabs Pharmaceutical Co., Ltd. has 4 drugs in our index: 1 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Shanghai Biomabs Pharmaceutical Co., Ltd.'s portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/shanghai-biomabs-pharmaceutical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Shanghai Biomabs Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Shanghai Biomabs Pharmaceutical Co., Ltd. pipeline: 1 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 2 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Target	Area
Remicade	Remicade	marketed	Tumor necrosis factor	Oncology
CMAB008	CMAB008	phase 3		Oncology
CMAB807 Injection	CMAB807 Injection	phase 3		Oncology

Therapeutic area mix

Oncology · 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Shanghai Biomabs Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Shanghai Biomabs Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shanghai-biomabs-pharmaceutical-co-ltd. Accessed 2026-05-17.